miR â122 promotes proliferation and invasion of clear cell renal cell carcinoma by suppressing Forkhead box O3
MicroRNAs (miRNAs) serve an important role in renal cancer, but renal cancer miRNA expression data remains inconsistent.12/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 5, 2018 Category: Urology & Nephrology Source Type: news
Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience
Sunitinib treatment has acceptable efficacy and safety profile in Malaysian mRCC patients. The MSKCC and IMDC factors are relevant for predicting survival in our patient cohort while HFS is a promising prognostic predictor which warrants further investigation.12/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 5, 2018 Category: Urology & Nephrology Source Type: news
Evolution of the NCCN Guidelines for Kidney Cancer -Tian Zhang
Tian Zhang and Charles Ryan highlight recent updates in the NCCN treatment guidelines for kidney cancer resulting from data leading to changes in treatment options. Incorporation of initial diagnosis, disease biology, risk category, and clinical factors assist with selecting the most appropriate therapy for these patients.11/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 21, 2018 Category: Urology & Nephrology Source Type: news
Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma
An analysis showed that fatty acid binding protein 7 (FABP7) has the highest mean differential overexpression in ccRCC compared to normal kidney.11/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 21, 2018 Category: Urology & Nephrology Source Type: news
Epidemiology of Renal Cell Carcinoma
Despite the improvement in renal cell carcinoma (RCC) diagnosis and management observed during the last 2 decades, RCC remains one of the most lethal urological malignancies. With the expansion of routine imaging for many disorders, an increasing number of patients who harbour RCC are identified incidentally.11/20/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 20, 2018 Category: Urology & Nephrology Source Type: news
A State of Flux for Kidney Cancer
11/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 19, 2018 Category: Urology & Nephrology Source Type: news
Trials Presented at ESMO 2018
In patients with previously untreated advanced renal cell carcinoma (RCC) whose tumors were positive for the PD-L1 checkpoint, a combination of the checkpoint inhibitor avelumab and the tyrosine kinase inhibitor (TKI) axitinib increased the median PFS from 8.4 months to 13.8 months when compared with the TKI sunitinib (HR 0.69; P=0.0001).11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and survival, and additionally plays an important role in immune regulation. Since mTOR inhibitors were shown to benefit immunosuppressive regulatory T-cell (Treg) expansion, this might suppress antitumor immune responses. Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news
CIP2A Promotes Proliferation, Invasion and Chemoresistance to Cisplatin in Renal Cell Carcinoma
CIP2A is a well-known oncoprotein whose expression is elevated in multiple human solid tumor types. However, its role in renal cell carcinoma (RCC) development is poorly understood.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news
The 11 most common cancers in the U.S.
Kidney cancer is one of the most common cancers in the U.S. Men are twice as likely as women to be diagnosed with kidney cancer, according to the ACS. Men's increased exposure to cancer-causing chemicals in the workplace and increased likelihood of smoking may partly explain this gap. For all people, though, the symptoms may include blood in the urine, low back pain on one side of the body that's not linked to an injury, a lump in the lower back, fatigue, appetite loss, unexplained weight loss, and more.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news
Clinical Trial Saves Life of Stage 4 Kidney Cancer Patient
Dallas journalist Robert Wilonsky beat the odds with help from the team at UT Southwestern.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news
Scientists identify potential new treatment strategy for kidney cancer
Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news
MDACC 2018: Debate: What is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma?
In this article, Dr. Gao defends Nivolumab plus ipilimumab as the best front-line systemic therapy for mRCC.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news
MDACC 2018: Debate: What is the Best Salvage Therapy After Failure of Immune Checkpoint Inhibition?
Dr. Msaouel discusses the best treatment options after failure of immune checkpoint inhibition.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news
